In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Endgame on Oncology Endpoints

Executive Summary

The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.

You may also be interested in...



Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On

Dendreon will have to wait until mid-2009 at the earliest for final study results of its prostate cancer vaccine Provenge, after it failed to meet the primary endpoint in an interim look at the data

Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection

As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials.

Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection

As cancer vaccine and immunotherapy developers try to get past the difficulties of recent years, they are looking to improve their chances for success by identifying the correct cancer types and settings to best respond to a specific vaccine and then choosing more meaningful endpoints for clinical trials

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel